- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02515266
Additional Protein Fortification in Extremely Low Birth Weight Infants (PROTSUP)
Evaluation of Additional Protein Fortification in Extremely Low Birth Weight Infants Fed Human Milk: PROTSUP Study
Postnatal growth is a crucial in premature infants as it could be correlated with the long-term cognitive development. Optimal nutritional care is required to reduce the initial weight loss and further growth deficit.
The quantitative objective is to achieve growth that is at least equivalent to that of the fetus (on average 15 g/kg.day (12-18 g/kg.day according to gestational age). Children often grow during difficult 10-15 first days of life, so they accumulate a delay that should compensate them secondarily. Therefore, optimum postnatal growth is rather 20 g/kg.day than 15 g/kg.day.
Individualized fortification of human milk (HM) has been proposed to optimize postnatal growth. Specifically, the lack of protein intake is responsible for sub-optimal postnatal growth in preterm infants.
The objectives of this study are to determine the effectiveness of additional protein fortification (APF) in terms of short-term growth along with the proportion of extremely low birth weight (ELBW) infants requiring APF.
Study Overview
Status
Intervention / Treatment
Detailed Description
In a retrospective, single-center study, premature infants weighing <1250 g at birth hospitalized in investigators' neonatal intensive care unit in 2012, who were exclusively fed with fortified HM and received APF for >12 consecutive days were included.
Weight gain (g/kg•d) over the previous 7 days was calculated daily based on weight data in patients' electronic medical records. When weight gain was considered insufficient (i.e., below 20 g/kg•d) and the serum urea level was <3 mmol/L, 1 g/kg•d protein was added. Before using the mixture, investigators verified that the osmolality was only slightly increased (from 412 to 422 mOsm/kg).
Growth and digestive tolerance were compared between the week before (Wk0) and 1 and 2 weeks after (Wk1 and Wk2, respectively) the introduction of protein supplement; each participant served as his own control. Change from baseline for body weight was the main outcome. Energy and protein intake during Wk0, Wk1, and Wk2 were calculated. Standard deviation z-scores for growth parameters were calculated 7 days before, at time of protein introduction, and 7 and 14 days after . Changes in Z-scores were calculated. The digestive tolerance score and metabolic tolerance (serum urea) were assessed during Wk0, Wk1, and Wk2 (5).
Study Type
Enrollment (Actual)
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- infants weighing <1250 g at birth
- exclusively fed with fortified HM
Exclusion Criteria:
- Severe malformations
Study Plan
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Change from baseline body weight z-scores to 1 and 2 weeks after additional protein fortification
Time Frame: One and two weeks after the beginning of additional protein fortification
|
One and two weeks after the beginning of additional protein fortification
|
Collaborators and Investigators
Sponsor
Investigators
- Study Director: Jean-charles PICAUD, MD, PhD, Hospices Civils de Lyon
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 20121
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Premature Birth
-
Shaare Zedek Medical CenterTerminatedPremature Birth of NewbornIsrael
-
University of VirginiaCompletedPremature Birth of NewbornUnited States
-
Case Western Reserve UniversityCompleted
-
University of California, San FranciscoUniversity of California, San Diego; University of California, Los Angeles; Kaiser...CompletedPremature Birth of NewbornUnited States
-
Universidad Complutense de MadridCompletedPremature Birth of Newborn
-
Indiana UniversityCompletedPremature LaborUnited States
-
Washington University School of MedicineUniversity of Southern CaliforniaCompletedPremature Birth of NewbornUnited States
-
University of ArkansasCompletedPremature Birth of NewbornUnited States
-
Elgan Pharma Ltd.Terminated
-
Hôpital de la Croix-RousseUnknownPremature Birth of NewbornFrance
Clinical Trials on nutrition: protein intake
-
Maastricht University Medical CenterNot yet recruitingNo Condition, Healthy IndividualsNetherlands
-
University of ArkansasDairy Research InstituteCompletedMetabolic Syndrome
-
University of Sao PauloUnknownCancer | Surgery | Critically IllBrazil
-
University of ArkansasCompleted
-
Kaiser PermanenteCompletedMalnutrition | Hypoalbuminemia | Peritoneal Dialysis ComplicationUnited States
-
The Hospital for Sick ChildrenCompleted
-
The Hospital for Sick ChildrenCompletedHealthy Males 65-75 Yrs OldCanada
-
University of British ColumbiaCanadian Institutes of Health Research (CIHR)Completed
-
Rajaie Cardiovascular Medical and Research CenterUnknownRenal Insufficiency | Heart Failure With Reduced Ejection Fraction